Sort by
Items per page

Send to

Choose Destination

Best matches for Liver cannabidiol:

Search results

Items: 1 to 20 of 137


The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.

Qian Y, Gilliland TK, Markowitz JS.

Chem Biol Interact. 2019 Dec 16;316:108914. doi: 10.1016/j.cbi.2019.108914. [Epub ahead of print]



LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2019 Apr 12.


Clobazam Therapy and CYP2C19 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2019 Sep 23.


A systematic review of cannabidiol dosing in clinical populations.

Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE.

Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi: 10.1111/bcp.14038. Epub 2019 Jul 19. Review.


Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain.

De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B.

Front Pharmacol. 2019 May 31;10:627. doi: 10.3389/fphar.2019.00627. eCollection 2019. Review.


Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration.

Ewing LE, McGill MR, Yee EU, Quick CM, Skinner CM, Kennon-McGill S, Clemens M, Vazquez JH, McCullough SS, Williams DK, Kutanzi KR, Walker LA, ElSohly MA, James LP, Gurley BJ, Koturbash I.

Molecules. 2019 Jun 17;24(12). pii: E2256. doi: 10.3390/molecules24122256.


Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.

Nona CN, Hendershot CS, Le Foll B.

Exp Clin Psychopharmacol. 2019 Aug;27(4):359-369. doi: 10.1037/pha0000272. Epub 2019 May 23. Review.


[Use of cannabidiol oil in children].

Wolff D, Reijneveld SA.

Ned Tijdschr Geneeskd. 2019 May 3;163. pii: D3145. Dutch.


Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.

Samanta D.

Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Review.


Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model.

Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I.

Molecules. 2019 Apr 30;24(9). pii: E1694. doi: 10.3390/molecules24091694.


Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-κB and NLRP3 inflammasome pathway.

Huang Y, Wan T, Pang N, Zhou Y, Jiang X, Li B, Gu Y, Huang Y, Ye X, Lian H, Zhang Z, Yang L.

J Cell Physiol. 2019 Nov;234(11):21224-21234. doi: 10.1002/jcp.28728. Epub 2019 Apr 29.


Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.

Perry MS.

Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671.


A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.

Taylor L, Crockett J, Tayo B, Morrison G.

J Clin Pharmacol. 2019 Aug;59(8):1110-1119. doi: 10.1002/jcph.1412. Epub 2019 Mar 28.


Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Mar;60(3):419-428. doi: 10.1111/epi.14670. Epub 2019 Feb 11.


A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. Review.


Decarbonylation: A metabolic pathway of cannabidiol in humans.

Kraemer M, Broecker S, Madea B, Hess C.

Drug Test Anal. 2019 Jul;11(7):957-967. doi: 10.1002/dta.2572. Epub 2019 Mar 20.


Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C.

Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.


Epilepsy and Cannabis: A Literature Review.

Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.

Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.


Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2019 Jan;93(1):179-188. doi: 10.1007/s00204-018-2322-9. Epub 2018 Oct 19.


A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome.

McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd.

Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi: 10.1002/acn3.621. eCollection 2018 Sep.

Supplemental Content

Loading ...
Support Center